Jinbo 锦波生物
5 significant filings since 31 May 2026: 2 on buyback, 1 on dividend and 1 on acquisition or disposal, and 1 other kind. The latest, on 23 Jun 2026: 高级管理人员变动公告.
自 31 May 2026 起有 5 份重大公告：buyback 2 份、dividend 1 份、acquisition or disposal 1 份，另有 1 类。最新一份（23 Jun 2026）：高级管理人员变动公告。
The tick on each bar marks the whole market, where 99.3% of rated reports in the same twelve months said Buy or Outperform. 刻度线为全市场水平：同期 99.3% 的评级为买入或跑赢。 Every rated report on this company said Buy or Outperform.
| Date 日期 | Broker 券商 | Analyst 分析师 | From 原评级 | To 新评级 | |
|---|---|---|---|---|---|
| 25 Apr 2025 | 东莞证券 | 吕子炜 | Outperform 增持 | ▲ | Buy 买入 |
| 31 Aug 2023 | 东吴证券 | 吴劲草,张家璇 | Outperform 增持 | ▲ | Buy 买入 |
Each broker's rating is compared with its previous report. 每家券商的评级与其上一份研报比较。
| Broker 券商 | Analyst 分析师 | Latest Rating 最新评级 | Date 日期 | Reports 研报 | Target 目标价 |
|---|---|---|---|---|---|
| 开源证券 | 诸海滨,车欣航 | Outperform 增持 | 9 Sep 2026 | 3 | — |
| 国金证券 | 杨欣,赵中平 | Buy 买入 | 27 Aug 2026 | 2 | — |
| 东吴证券 | 吴劲草,朱国广,朱洁羽,冉胜男,郗越 | Buy 买入 | 6 May 2026 | 1 | — |
Each row is a broker's latest report in the last twelve months. A price target is given in 0 of 6 reports. 每行为该券商近十二个月的最新研报；6 份中 0 份给出目标价。
Each bar counts the brokers publishing on this company in a quarter. The latest quarter is not yet complete. 每根柱为该季度发布本公司研报的券商数，最近一个季度尚未结束。